Compounds for the Treatment of Systemic Insulin Resistance Disorders and the Use Thereof
申请人:Galectin Sciences, LLC
公开号:US20200061095A1
公开(公告)日:2020-02-27
Aspects of the invention relate to novel synthetic compounds for treatment of metabolic diseases partially associated with systemic insulin resistance caused by Galectin proteins binding and inhibiting insulin and TGFb1 receptors causing physiological disturbances in the insulin pathways.